Evidence map›Paper›PMID 37599905›Full record

ArticleEClinicalMedicine2023

Large-scale identification of undiagnosed hepatic steatosis using natural language processing.

Carolin V Schneider, Tang Li, David Zhang, Anya I Mezina, Puru Rattan, Helen Huang, Kate Townsend Creasy, Eleonora Scorletti, Inuk Zandvakili, Marijana Vujkovic and 11 more

Open access · goldAbstract read
In one paragraph

Article in EClinicalMedicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
4.9field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Deep metabolic phenotyping of humans with protein-altering variants inJHEP reports : innovation in hepatology · 2025
    Article
  12. MedComm · 2025
    Article
  13. Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 5 institutions in 2 countries.

Carolin V SchneiderDivision of Translational Medicine and Human Genetics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Tang LiDepartment of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
David ZhangDivision of Translational Medicine and Human Genetics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Anya I MezinaDivision of Gastroenterology and Hepatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Puru RattanDivision of Gastroenterology and Hepatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Helen HuangDivision of Translational Medicine and Human Genetics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Kate Townsend CreasyDivision of Translational Medicine and Human Genetics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Eleonora ScorlettiDivision of Translational Medicine and Human Genetics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Inuk ZandvakiliDivision of Translational Medicine and Human Genetics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Marijana VujkovicDivision of Translational Medicine and Human Genetics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Leonida HehlDepartment of Medicine III, RWTH Aachen University, Aachen, Germany.
Jacob FikselDepartment of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Joseph ParkDivision of Translational Medicine and Human Genetics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Kirk WangensteenDepartment of Medicine, Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55902, USA.
Marjorie RismanDivision of Translational Medicine and Human Genetics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Kyong-Mi ChangDivision of Gastroenterology and Hepatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Marina SerperDivision of Gastroenterology and Hepatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Rotonya M CarrDepartment of Medicine, Division of Gastroenterology, University of Washington, Seattle, WA 98195, USA.
Kai Markus SchneiderDepartment of Medicine III, RWTH Aachen University, Aachen, Germany.
Jinbo ChenDepartment of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Daniel J RaderDivision of Translational Medicine and Human Genetics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
University of Pennsylvania · USPhiladelphia VA Medical Center · USRWTH Aachen University · DEMayo Clinic in Arizona · USUniversity of Washington · US

Funding

Phenotypic Diversity in COVID-19UL1TR001878 · NCATS · UNIVERSITY OF PENNSYLVANIA · PI FITZGERALD, GARRET A · 2016 to 2025
$102.4M
UNIVERSITY OF PENNSYLVANIA TRAINING IN GASTROENTEROLOGYT32DK007066 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI JONATHAN P KATZ · 1986 to 2026
$11.7M
Molecular Mechanisms Of Post-Transplant Recurrent Alcoholic Liver DiseaseR01AA026302 · NIAAA · UNIVERSITY OF WASHINGTON · PI ROTONYA M CARR · 2017 to 2026
$3.2M
Molecular mechanisms underlying the genetic association between PPP1R3B and hepatic steatosisR01DK114291 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI BAUR, JOSEPH A., RADER, DANIEL JAMES · 2018 to 2021
$2.9M
A genomics-based strategy to precision phenotyping and drug repositioning in cardiometabolic diseasesR01DK134575 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI Marijana Vujkovic · 2023 to 2026
$1.4M
Statistical Methods for Analyzing Electronic Health Record DataR01HL138306 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI CHEN, JINBO · 2018 to 2020
$1.2M
Hereditary Genetics of Hepatocellular CarcinomaR01CA259201 · NCI · UNIVERSITY OF PENNSYLVANIA · PI WANGENSTEEN, KIRK J · 2022 to 2022
$178k
BLRD VA I01 BX003362NCATS NIH HHS UL1 TR001878NCI NIH HHS R01 CA259201NHLBI NIH HHS R01 HL138306NIAAA NIH HHS R01 AA026302NIDDK NIH HHS R01 DK114291NIDDK NIH HHS R01 DK134575NIDDK NIH HHS T32 DK007066
6 · The paper itself

Abstract

Background: Nonalcoholic fatty liver disease (NAFLD) is a major cause of liver-related morbidity in people with and without diabetes, but it is underdiagnosed, posing challenges for research and clinical management. Here, we determine if natural language processing (NLP) of data in the electronic health record (EHR) could identify undiagnosed patients with hepatic steatosis based on pathology and radiology reports. Methods: A rule-based NLP algorithm was built using a Linguamatics literature text mining tool to search 2.15 million pathology report and 2.7 million imaging reports in the Penn Medicine EHR from November 2014, through December 2020, for evidence of hepatic steatosis. For quality control, two independent physicians manually reviewed randomly chosen biopsy and imaging reports (n = 353, PPV 99.7%). Findings: After exclusion of individuals with other causes of hepatic steatosis, 3007 patients with biopsy-proven NAFLD and 42,083 patients with imaging-proven NAFLD were identified. Interestingly, elevated ALT was not a sensitive predictor of the presence of steatosis, and only half of the biopsied patients with steatosis ever received an ICD diagnosis code for the presence of NAFLD/NASH. There was a robust association for Interpretation: This study demonstrates clear feasibility of NLP-based approaches to identify patients whose steatosis was indicated in imaging and pathology reports within a large healthcare system and uncovers undercoding of NAFLD in the general population. Identification of patients at risk could link them to improved care and outcomes. Funding: The study was funded by US and German funding sources that did provide financial support only and had no influence or control over the research process.

Indexed as

BiopsyEHRLiver diseaseNAFLDNatural language processing

Identifiers

PMID37599905
PMCPMC10432816
OpenAlexW4385701679

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.